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Introduction
Conventional nonsteroidal anti-inflammatory drugs (NSAIDs)
are widely used for treating different pathological conditions,
from small injuries, headache or fever to chronic and severe
pain. The efficacy of this class of drugs in relieving inflamma-
tion is related to their capability to inhibit cyclooxygenase
(COX) enzymes, thus preventing the production of prostaglan-
dins from arachidonic acid. While the therapeutic effects are
primarily mediated by cyclooxygenase-2 (COX-2) inhibition, the
inhibition of cyclooxygenase-1 (COX-1) is responsible for the
side effects of NSAIDs, including renal and gastrointestinal (GI)
toxicities. For this reason, a class of drugs that selectively inhib-
it the COX-2 isoform (coxibs) has been developed and market-
ed.[1, 2] However, the complete inhibition of COX-2 has led to
a lack of a balance in the prostanoid production at cardiovas-
cular (CV) level and as a consequence, the long-term adminis-
tration of coxibs resulted in an increased incidence of throm-
botic events and a greater CV hazard in many patients.[3–6]
Therefore, different strategies have been adopted to obtain
safer anti-inflammatory agents, with limited gastrointestinal
and cardiovascular toxicity.[7, 8] A valuable option is to design
multitarget-directed ligands, combining pharmacophoric ele-
ments that are able to simultaneously modulate different tar-
gets into the same scaffold, in order to either decrease side ef-
fects or enhance anti-inflammatory activity.[9] Dual fatty acid
amide hydrolase (FAAH)/COX inhibitors are a representative ex-
ample of this class of drugs.[10]
Another interesting strategy to decrease side effects due to
COX inhibition is to develop “molecular hybrids” conjugating
the COX-inhibiting scaffold with a moiety able to counteract
side effects, such as a nitric oxide (NO) releasing group.[11, 12]
NO is a small endogenous gasotrasmitter produced by three
isozymes (NOS, NO synthases) in many cells and plays a pivotal
role in blood pressure regulation, cell proliferation, vascular ho-
meostasis and vasorelaxant processes.[13,14] Due to its small size
and to its very high reactivity, it serves as a potent local modu-
lator that rapidly diffuses through membranes to target cells
and it is involved in cell-to-cell communication.[15] In the CV
system it acts as a physiological vasodilator and mediates
smooth muscle relaxation by modulating the soluble guanylyl
cyclase–cyclic guanosine monophosphate (sGC-cGMP) path-
way.[16] It also inhibits platelet aggregation and is likely to pre-
vent both early and later steps of atherogenesis by decreasing
leucocyte adhesion to the vascular wall.[17] In addition, it can
regulate gastric blood flow and contribute to gastric mucosal
defense by modulating mucus and bicarbonate secretion.[18]
The first example of COX-inhibiting nitric oxide donors
Herein we report the synthesis, biological evaluation, and
docking analysis of a class of cyclooxygenase-2 (COX-2) inhibi-
tors with nitric oxide (NO)-releasing properties. In an earlier
study, a number of selective COX-2 inhibitors/NO donors were
developed by conjugating a diarylpyrrole scaffold endowed
with selective COX-2 inhibitory properties with various nitroox-
yalkyl side chains such as esters, a-amino esters, amides, a-
amino amides, ethers, b-amino ethers, inverse esters, and
amides. These candidates were found to have high in vitro po-
tencies (COX-2 inhibition at 10 mm: 96%), great efficacy in
determining NO-vasorelaxing responses, and good antinoci-
ceptive activity in an abdominal writhing test. Among the
compounds synthesized in the present work, derivative 2b [2-
(2-(1-(3-fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-1H-
pyrrol-3-yl)acetamido)ethyl nitrate] showed particularly out-
standing activity, with efficacy similar to that of celecoxib even
at very low concentrations.
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(CINODs) is naproxcinod (AZD3582, produced by NicOx), result-
ing from the conjugation of a NO-releasing moiety to a NSAID
scaffold.[12] Hereafter, given the key role of NO at CV level, this
strategy was applied to COX-2-selective inhibitors, in order to
obtain more potent anti-inflammatory agents with an abated
GI toxicity and an acceptable CV safety profile.[19–23]
In this context, we developed a number of selective COX-2
inhibitors/nitric oxide donors by conjugating a diarylpyrrole
scaffold endowed with selective COX-2 inhibition proper-
ties[24–32] with different nitrooxyalkyl side chains, such as esters,
a-amino esters, amides, a-amino amides, ethers, b-amino
ethers, inverse esters and amides.[33–37] This medicinal chemistry
program led to the identification of very promising candidates
(Figure 1), with high in vitro potencies (COX-2 inhibition at
10 mm96%), a great efficacy in determining NO-vasorelaxing
responses and a good antinociceptive activity in the abdomi-
nal writhing test (46–77% decrease in writhing at 10 mgkg¢1).
To complete the picture, we present herein the development
of a new class of sulfamoyl pyrroles as COX-2 inhibitors and
NO donors. Indeed, assuming that the lower logP of arylsulfo-
namides could contribute to improved bioavailability and ab-
sorption with respect to arylsulfones, we explored the replace-
ment of the methylsulfonyl moiety with a sulfamoyl one, to
further improve in vivo activity.[31,38] Thus, we prepared the ni-
trooxy acetic esters and amides 1–2 bearing a C5 sulfamoyl-
phenyl group and a fluorinated N1 phenyl ring, according to
structure–activity relationship (SAR) data emerged from the
previously synthesized compounds. Finally, considering that
such compounds undergo in vivo metabolism and that they
could in turn be converted into the corresponding alcohols
after NO release, the hydroxy derivatives 3–4 were synthesized
and tested as probable metabolites (Figure 2).
Results and Discussion
Chemistry
Compounds 1–4 were prepared following the synthetic path-
way described in Scheme 1. The acetic acid derivatives 5a,b
were synthesized as previously reported.[31] Briefly, derivatives
1–3 were obtained through a coupling reaction between 2-hy-
droxyethyl nitrate, 2-aminoethyl nitrate or ethylene glycol and
the suitable acid 5a,b in the presence of 4-dimethylaminopyri-
dine (DMAP), N’-(3-dimethylaminopropyl)-N-ethylcarbodiimide
(EDCI), and triethylamine (TEA). On the other hand, the hy-
droxy derivatives 4a,b were obtained via an EDCI/1-hydroxy-
benzotriazole (HOBt) coupling stage.
In vitro studies
Inhibition of COX-1/COX-2 was assessed through an enzyme
immunoassay and the prostanoids were quantified using the
commercially available COX Inhibitor Screening Assay (Cayman
Chemical Company, Ann Arbor, MI, USA). Data are reported as
percent inhibition for all the tested compounds, and as IC50
values for the two most active ones (1a and 1b, Table 1).
As reported in Table 1, nitrated acetic esters 1a,b displayed
the best activities against COX-2, with IC50 values of 1.170.06
and 0.410.01 mm, respectively. Such derivatives were found
to be much more active than the corresponding hydroxy deriv-
atives 3a,b, confirming the same trend observed for the meth-
ylsulfonyl analogues.[33] On the other hand, the presence of the
amide fragment was responsible for a drop in activity; in fact,
both the acetic amides 2a and 2b proved to be less active
than the corresponding acetic esters, proving that the combi-
nation of a nitroxyalkyl chain with an ester moiety guarantees
the best interactions within the binding site.
Figure 1. Structures of the most promising compounds previously synthe-
sized.
Figure 2. Structures of compounds 1–4.
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Ex vivo NO releasing studies
The capability of nitrooxy derivatives 1–2 in determining vaso-
relaxing responses was assessed using rat endothelium-denud-
ed aortic rings pre-contracted with KCl (30 mm) as an experi-
mental model of vascular smooth muscle. Because NO induces
vasodilator responses by activating GC and consequently in-
creasing cGMP levels, the experiments were also performed in
the presence of a GC inhibitor (1H-[1,2,4]oxadiazolo[4,3-a]qui-
noxalin-1-one, ODQ), to confirm their mechanism of action. As
reported in Table 2, all the tested compounds were effective in
inducing vasorelaxing responses. In particular, the nitrooxy
amides 2a,b showed the best activity, with values of efficacy
(Emax) and potency (pIC50) similar to those of naproxcinod, used
as a control. Moreover, all the tested compounds were found
to be inactive in the presence of ODQ, proving that their effi-
cacy was due to NO release. Notably, no vasorelaxing effect
was observed at low concentrations, suggesting that these
compounds gradually release NO (Figure 3); as a consequence,
they are not responsible for a massive hypotensive effect
in vivo, that is an essential feature for hybrid drugs.
Scheme 1. Synthesis of compounds 1–4. Reagents and conditions : a) 2-nitrooxyethanol, DMAP, EDCI, TEA, CH2Cl2/DMF 10:1 (v/v), 15 h, RT; b) 2-nitrooxyethyla-
mine, DMAP, EDCI, TEA, CH2Cl2/DMF 10:1 (v/v), 15 h, RT; c) ethylene glycol, DMAP, EDCI, TEA, CH2Cl2/DMF 10:1 (v/v), 15 h, RT; d) ethanolamine, HOBt, EDCI,
CH2Cl2/DMF 10:1 (v/v), 15 h, RT.
Table 1. In vitro activities of compounds 1–4 and reference compound
Dup-697 towards COX-1 and COX-2.
Compd Inhibition [%][a] COX-2 IC50 [mm]
[d]
COX-1 COX-2
1a n.a.[b] 86 1.170.06
1b n.a.[b] 89 0.410.01
2a n.t.[c] 16 n.d.[e]
2b n.t.[c] 45 n.d.[e]
3a n.t.[c] 16 n.d.[e]
3b n.t.[c] n.a.[b] n.d.[e]
4a n.t.[c] 18 n.d.[e]
4b n.t.[c] 15 n.d.[e]
Dup-697 – 100 –
[a] Each value is the mean of at least three determinations at a test com-
pound concentration of 10 mm, carried out in triplicate; SEM5%.
[b] Not active: no inhibition was observed at 10 mm. [c] Not tested.
[d] Values are the meanSD of at least three determinations, carried out
in triplicate. [e] Not determined.
Table 2. Nitric oxide releasing efficacy and potency for compounds 1–2
and naproxcinod, used as reference compound.
Compound Emax
[a] pIC50
[b] +ODQ (1 mm)
1a 470.5 n.c.[c] +
1b 59.10.4 5.550.07 +
2a 74.92.5 5.820.04 +
2b 67.52.3 5.490.00 +
naproxcinod 68.03.0 6.330.06 +
[a] Vasorelaxing efficacy was evaluated as the maximal vasorelaxing re-
sponse (Emax), expressed as a percentage of the contractile tone induced
by KCl (30 mm). [b] Potency is expressed as pIC50, which was calculated
as the negative logarithm of the molar concentration of the tested com-
pounds required to evoke a half decrease in the contractile tone induced
by KCl (30 mm). [c] Not calculated.
ChemMedChem 2016, 11, 1804 – 1811 www.chemmedchem.org Ó 2016 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim1806
Full Papers
In vivo studies: decrease in writhing in acetic acid induced
abdominal constrictions in mice
Based on their in vitro potencies, compounds 1–2 and 4b
were selected to assess their analgesic efficacy in a murine
model of inflammatory pain. Such derivatives were orally ad-
ministered 30 min before inducing writhing using an acetic
acid intraperitoneal injection. Afterward, the number of writhes
was measured and the results were expressed as a percentage
of writhing decreased in comparison with the vehicle-treated
mice (Table 3). All the tested compounds proved to be effec-
tive in reducing writhing. However, the nitrooxy amides 2a,b
exhibited a better pharmacological profile with respect to the
acetic esters, differently from what emerged from the in vitro
results. Indeed, the acetic esters 1a,b were almost inactive at
low doses, showing an appreciable efficacy only when adminis-
tered at doses higher than 10 mgkg¢1. Interestingly, acetic
ester 1b was as active as the methylsulfonyl analogue MAB103
only in the 20 mgkg¢1 range (MAB103 writhing inhibition at
20 mgkg¢1: 47.5%), while it was even active at 10 mgkg¢1
(MAB103 is inactive below 20 mgkg¢1).[33] On the other hand,
the acetic amides showed good activities also in the 1–
10 mgkg¢1 range, probably because they are endowed with
both a greater solubility and a higher stability, as previously
demonstrated for the methylsulfonyl analogues.[37] Therefore,
their improved pharmacokinetic properties might counterbal-
ance the lower affinity for the enzyme. Derivative 2b exhibited
a unique profile : being the most active in the 3–10 mgkg¢1
range, its efficacy was also evaluated at lower doses and it
proved to be significantly effective even at 1 mgkg¢1 (35% de-
crease in writhing), with an efficacy similar to that of celecoxib
and better than that of the methylsulfonyl analogue MAB137
(inactive below 3 mgkg¢1).[37] Finally, the hydroxy compound
4b was found to be less active than the corresponding nitro-
oxyl analogue, confirming the trend observed for the previous-
ly synthesized compounds.
Structure-based studies
As previously reported, Vina was determined to be the most
suitable docking program to study the binding mode of COX-2
inhibitors.[31] Therefore, the newly synthesized compounds
were all cross-docked by means of this program. In particular,
compounds were modeled and cross-docked into all the avail-
able COX-2 experimental structures following the docking pro-
tocol previously reported.[31] The lowest-energy poses were se-
lected as the likely binding modes for the newly synthesized
compounds. In general the new derivatives were found to
dock into COX-2 similarly to the previously reported com-
pounds.[31] To avoid redundancy, the binding mode described
here focuses on the most active compound in vivo 2b (see
Table 3), which was found to inhibit COX-2 (see Table 1). The
lowest energy docked pose of 2b was found in the celecoxib/
COX-2 experimental complex (PDB ID: 3LNI) displaying a bind-
ing mode highly superimposable to that of the reference com-
pound (Figure 4). The three aromatic portions of the two com-
pounds are highly overlapped and only small differences are
visible for the 3-fluorophenyl group of 2b and the 4-methyl-
phenyl group of celecoxib, i.e. , the former is slightly rotated by
~30 degrees to allow accommodation of the 3-fluoro substitu-
ent. Differently from celecoxib, the 2b side chain fills a pocket
formed mainly by hydrophobic residues (Met113, Val116,
Leu117, Val344, Ile345, Val349, Leu359, Ser530, Leu531 and
Leu534) and a moderate hydrogen bond distance is observa-
ble among the distal nitro group and the Ser530 side chain hy-
droxy group (Ser513-NO2···HOSer513=3.02 æ).
Figure 3. Concentration–response curve for the vasorelaxing effects exerted
by compounds 1–2. The experiments were performed both in the presence
and absence of ODQ (1 mm). Data are the meanSEM of n=6 experiments
performed in sextuplicate.
Table 3. Effects of 1–2, 4b and celecoxib in the mouse abdominal con-
striction test (acetic acid, 0.6%).
Treatment #Mice Dose
[mgkg¢1 p.o.][a]
#Writhes Writhes
decrease [%]
CMC 28 – 33.62.2 –
1a 5 10 27.63.5 17.8
1a 6 30 19.02.9 43.4
1b 10 5 30.63.7 8.9
1b 10 10 18.93.0[b] 43.7
1b 8 20 17.83.4[b] 47.0
2a 10 5 26.73.3 20.5
2a 10 10 18.54.2[b] 44.9
2a 8 20 15.83.7[b] 53.0
2a 9 40 16.72.5[b] 50.3
2b 5 1 21.83.5[b] 35.1
2b 5 3 19.42.9[b] 42.3
2b 6 10 16.73.5[b] 50.3
4b 7 3 26.42.5[c] 21.4
4b 8 10 23.83.1 29.2
4b 6 30 21.22.7[b] 36.9
celecoxib 10 1 19.32.5 42.5
celecoxib 10 5 16.62.2 50.6
celecoxib 10 10 14.22.3 57.7
celecoxib 10 20 13.92.7 58.6
celecoxib 10 40 10.22.1 69.6
[a] All drugs were administered per os 30 min before test. [b] p<0.01,
[c] p<0.05 versus vehicle-treated mice.
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Conclusions
We report the further structural modification of a series of
pharmacodynamic hybrids based on a 1,5-diarylpyrrole scaf-
fold. Some of the newly synthesized compounds were endow-
ed with a good affinity for COX-2, proving that the replace-
ment of methylsulfonylphenyl moiety at the C5 of the pyrrole
ring does not significantly affect the affinity for the target
enzyme. The nitrooxyl derivatives 1–2 also exhibited good vas-
orelaxing properties, due to NO release. Overall, the tested
compounds exhibited a good in vivo pharmacological profile
and they all proved to be able to decrease writhing in
a murine model of inflammatory pain. In particular, derivative
2b is characterized by an outstanding in vivo potency and
proved to be effective even at 1 mgkg¢1, showing a lower ef-
fective dose with respect to the most potent methylsulfonyl
analogue previously synthesized (MAB137). Structure-based
studies confirmed that it docks into COX-2 adopting a confor-
mation highly superimposable to that of celecoxib, used as
a reference compound. Being the most promising derivative of
this class, further studies will address its pharmacokinetic pro-
file and evaluate the contribution of the sulfamoyl moiety to
its solubility and its bioavailability.
Experimental Section
Chemistry
All chemicals used were of reagent grade. Yields refer to purified
products and are not optimized. Melting points were determined
in open capillaries on a Gallenkamp apparatus and were uncorrect-
ed. Sigma–Aldrich silica gel 60 (230–400 mesh) was used for
column chromatography. Merck TLC plates (silica gel 60F254) were
used for thin-layer chromatography (TLC). 13C NMR and 1H NMR
spectra were recorded with a Bruker AC 400 spectrometer in the
indicated solvent (TMS as the internal standard). The values of the
chemical shifts are expressed in d. Mass spectra were recorded on
an API-TOF Mariner by Perspective Biosystem (Stratford, TX, USA).
Compound purity was assessed by elemental analysis obtained
with a PE 2400 analyzer (PerkinElmer). The purity of target com-
pounds was >95%.
General procedure for the preparation of nitrooxyalkyl and hy-
droxyalkyl esters 1a,b and 3a,b : To a solution of the appropriate
acid (5a,b) (0.200 g, 0.54 mmol) in a mixture of CH2Cl2/N,N-dime-
thylformamide (DMF) (10:1 (v/v), 7 mL), the suitable alcohol
(0.8 mmol), DMAP (0.109 g, 0.65 mmol), EDCI (0.106 g, 0.87 mmol)
and TEA (0.11 mL, 0.65 mmol) were added in sequence under a ni-
trogen atmosphere. The reaction was quenched after 15 h with
water (10 mL) and extracted with CH2Cl2 (50 mLÕ3). The organic
layer was washed with 1n HCl (50 mL), NaHCO3 saturated solution
(50 mL), brine (50 mL) and dried over Na2SO4. The organic phase
was then filtrated and concentrated under reduced pressure to
give a crude product that was purified on silica gel using a mixture
of cyclohexane/ethyl acetate (2:1 (v/v)) as eluent to give derivatives
1a,b and 3a,b as pale-yellow and white powders, respectively.
2-(Nitrooxy)ethyl 2-(1-(4-fluorophenyl)-2-methyl-5-(4-sulfamoyl-
phenyl)-1H-pyrrol-3-yl)acetate (1a): Pale-yellow powder, (0.162 g,
63% yield); mp: 109 8C; 1H NMR (400 MHz CDCl3): d=2.05 (s, 3H,
CH3 pyrrolic), 3.51 (s, 2H, C-CH2-CO), 4.43 (t, J=3.18 Hz, 2H, CO-O-
CH2-CH2-ONO2), 4.75 (t, J=3.18 Hz, 2H, CO-O-CH2-CH2-ONO2), 4.78
(br s, 2H, SO2NH2), 6.48 (s, 1H, CH pyrrolic), 7.17–7.28 (m, 6H, H
arom.), 7.68 ppm (d, J=7.34 Hz, 2H, H arom.); 13C NMR (100 MHz,
CDCl3): d=169.5, 158.8, 146.6, 143.4, 142.5, 134.9, 127.8, 126.4,
123.1, 122.6, 121.8, 117.0, 114.4, 66.2, 62.3, 34.8, 10.3 ppm; IR (KBr):
n˜=3390, 3300, 1752, 1630 cm¢1; ESIMS: m/z 500.09 [M+Na]+ ;
HRMS-FAB m/z [M+H]+ calcd for C21H20FN3O7S: 477.1006, found:
477.1003; Anal. calcd for C21H20FN3O7S: C 52.83, H 4.22, N 8.80, O
23.46, found: C 52.80, H 4.25, N 8.82, O 23.47.
2-(Nitrooxy)ethyl 2-(1-(3-fluorophenyl)-2-methyl-5-(4-sulfamoyl-
phenyl)-1H-pyrrol-3-yl)acetate (1b): Pale-yellow powder, (0.149 g,
58% yield); mp: 102 8C; 1H NMR (400 MHz CDCl3): d=2.09 (s, 3H,
CH3 pyrrolic), 3.55 (s, 2H, C-CH2-CO), 4.43 (t, J=3.18 Hz, 2H, CO-
CH2-CH2-ONO2), 4.71 (t, J=3.18 Hz, 2H, CO-CH2-CH2-ONO2), 4.75
(br s, 2H, SO2NH2), 6.48 (s, 1H, CH pyrrolic), 6.90 (d, J=7.34 Hz, 1H,
H arom.), 6.96 (d, J=7.34 Hz, 1H, H arom.), 7.07–7.19 (m, 3H, H
arom.), 7.39–7.37 (m, 1H, H arom.), 7.68 ppm (d, J=7.34 Hz, 2H, H
arom.); 13C NMR (100 MHz, CDCl3): d=169.5, 163.8, 144.6, 143.4,
142.5, 134.9, 131.2, 127.5, 127.0, 126.4, 122.6, 117.0, 114.4, 111.1,
106.5, 69.2, 62.3, 34.8, 10.3 ppm; IR (KBr): n˜=3366, 3255, 1749,
1620 cm¢1; ESIMS: m/z 500.09 [M+Na]+ ; HRMS-FAB m/z [M+H]+
calcd for C21H20FN3O7S: 477.1006, found: 477.1003; Anal. calcd for
C21H20FN3O7S: C 52.83, H 4.22, N 8.80, O 23.46 found: C 52.80, H
4.25, N 8.78, O 23.47.
2-Hydroxyethyl 2-(1-(4-fluorophenyl)-2-methyl-5-(4-sulfamoyl-
phenyl)-1H-pyrrol-3-yl)acetate (3a): White powder, (0.107 g, 43%
yield); mp: 131 8C; 1H NMR (400 MHz, [D6]DMSO): d=1.98 (s, 3H,
CH3 pyrrolic), 3.50 (s, 2H, C-CH2-CO), 3.58 (t, J=3.20 Hz, 2H, CO-O-
CH2-CH2-OH), 4.05 (t, J=3.20 Hz, 2H, CO-O-CH2-CH2-OH), 4.81 (br s,
1H, OH), 6.46 (s, 1H, CH pyrrolic), 7.11 (d, J=8.07 Hz, 2H, H arom.)
7.22–7.27 (m, 6H, H arom. and SO2NH2), 7.57 ppm (d, J=8.07 Hz,
2H, H arom.); 13C NMR (100 MHz, [D6]DMSO): d=169.5, 158.8,
146.6, 143.4, 142.5, 134.9, 127.8, 126.4, 123.1, 122.6, 121.8, 117.0,
Figure 4. Docked proposed 2b (gray carbon atoms) binding mode into the
binding site of PDB ID: 3LNI. For comparison, the co-crystallized celecoxib is
also depicted (light magenta carbon atoms). The figure was generated using
UCSF Chimera 1.10.2. The surface of Met113, Val116, Leu117, Val344, Ile345,
Val349, Leu359, Ser530, Leu531 and Leu534 residues is displayed to high-
light the 2b side chain binding pocket.
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114.4, 66.2, 62.3, 34.8, 10.3 ppm; IR (KBr): n˜=3350, 3256,
1760 cm¢1; ESIMS: m/z 455.10 [M+Na]+ ; HRMS-FAB m/z [M+H]+
calcd for C21H21FN2O5S: 432.1155, found: 432.1150; Anal. calcd for
C21H21FN2O5S: C 58.32, H 4.89, N, 6.48, O 18.50 found: C 58.35, H
4.91, N, 6.53, O 18.45.
2-Hydroxyethyl 2-(1-(3-fluorophenyl)-2-methyl-5-(4-sulfamoyl-
phenyl)-1H-pyrrol-3-yl)acetate (3b): White powder, (0.107 g, 46%
yield); mp: 121 8C; 1H NMR (400 MHz, [D6]DMSO): d=2.01 (s, 3H,
CH3 pyrrolic), 3.50 (s, 2H, C-CH2-CO), 3.58 (t, J=3.16 Hz, 2H, CO-O-
CH2-CH2-OH), 4.06 (t, J=3.16 Hz, 2H, CO-O-CH2-CH2-OH), 4.81 (br s,
1H, OH), 6.48 (s, 1H, CH pyrrolic), 7.01 (d, J=7.37 Hz, 1H, H arom.)
7.12 (d, J=7.37 Hz, 2H, H arom.), 7.25–7.30 (m, 4H, H arom. and
SO2NH2), 7.41–7.45 (m, 1H, H arom.), 7.51 ppm (d, J=7.37 Hz, 2H,
H arom.); 13C NMR (100 MHz, [D6]DMSO): d=169.5, 158.8, 146.6,
143.4, 142.5, 134.9, 131.7, 127.8, 126.4, 123.1, 121.8, 117.0, 114.4,
11.8, 108.5, 66.2, 62.3, 34.8, 10.3 ppm; IR (KBr): n˜=3383, 3350,
1765 cm¢1; ESIMS: m/z 455.10 [M+Na]+ ; HRMS-FAB m/z [M+H]+
calcd for C21H21FN2O5S: 432.1155, found: 432.1159; Anal. calcd for
C21H21FN2O5S: C 58.32, H 4.14, N 6.48, O 18.76 found: C 58.35, H
4.20, N 6.45, O 18.73.
General procedure for the preparation of nitrooxyalkyl amides
2a,b : 2-aminoethylnitrate salt (0.203 g, 1.2 mmol), DMAP (0.164 g,
0.97 mmol) and EDCI (0.159 g, 1.3 mmol) were added in sequence
to a solution of the acid partner (5a,b) (0.300 g, 0.81 mmol) dis-
solved in a mixture of CH2Cl2/DMF 10:1 (v/v) (10 mL), under a nitro-
gen flow. An excess of TEA (0.17 mL, 1.3 mmol) was then added
dropwise and the reaction was stirred at room temperature (RT)
for 12 h. The mixture was then quenched with water (10 mL) and
extracted with CH2Cl2 (50 mLÕ3). The organic layer was washed
with 1n HCl (50 mL), NaHCO3 saturated solution (50 mL), brine
(50 mL) and dried over Na2SO4. After filtration and concentration of
the organic phase a crude material was obtained and was purified
by chromatography on silica gel using as eluent a mixture of cyclo-
hexane/ethyl acetate (1:1 (v/v)), affording compounds 2a,b as
pale-yellow powders.
2-(2-(1-(4-Fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-1H-
pyrrol-3-yl)acetamido)ethyl nitrate (2a): Pale-yellow powder,
(0.237 g, 50% yield); mp: 127 8C; 1H NMR (400 MHz, [D6]DMSO): d=
1.97 (s, 3H, CH3 pyrrolic), 3.26 (s, 2H, C-CH2-CO) 3.37 (t, J=5.01 Hz,
2H, CO-NH-CH2-CH2-ONO2), 4.54 (t, J=5.01 Hz, 2H, CO-NH-CH2-
CH2-ONO2), 6.43 (s, 1H, CH pyrrolic), 7.09 (d, J=8.07 Hz, 2H, H
arom.), 7.21–7.29 (m, 6H, arom. and SO2NH2), 7.56 (d, J=8.07 Hz,
2H, H arom.), 8.11 ppm (br s, 1H, CONH) ; 13C NMR (100 MHz,
[D6]DMSO): d=169.5, 158.8, 146.6, 143.4, 142.5, 134.9, 127.8, 126.4,
123.1, 122.6, 121.8, 117.0, 114.4, 72.5, 36.2, 34.8, 10.3 ppm; IR (KBr):
n˜=2967, 2923, 1735, 1637 cm¢1; ESIMS: m/z 499.11 [M+Na]+ ;
HRMS-FAB m/z [M+H]+ calcd for C21H21FN4O6S: 477.1166, found:
477.1158; Anal. calcd for: C21H21FN4O6S: C 52.94, H 4.44, N 11.76, O
20.15, found: C 53.00, H 4.43, N 11.70, O 20.13.
2-(2-(1-(3-Fluorophenyl)-2-methyl-5-(4-sulfamoylphenyl)-1H-
pyrrol-3-yl)acetamido)ethyl nitrate (2b): Pale-yellow powder,
(0.242 g, 51% yield); mp: 125 8C; 1H NMR (400 MHz, [D6]DMSO): d=
2.03 (s, 3H, CH3 pyrrolic), 3.28 (s, 2H, C-CH2-CO), 3.43 (t, J=5.14 Hz,
2H, CO-NH-CH2-CH2-ONO2), 4.57 (t, J=5.14 Hz, 2H, CO-NH-CH2-
CH2-ONO2), 6.46 (s, 1H, CH pyrrolic) 7.02 (d, J=8.31 Hz, 1H, H
arom.), 7.13 (d, J=8.31 Hz, 2H, H arom.), 7.18–7.33 (m, 4H, H arom.
and SO2NH2), 7.51–7.57 (m, 1H, H arom.), 7.61 (d, J=8.31 Hz, 2H, H
arom.), 8.15 ppm (br s, 1H, CONH) ; 13C NMR (100 MHz, [D6]DMSO):
d=169.5, 158.8, 146.6, 143.4, 142.5, 134.9, 131.6, 127.8, 126.3,
125.2, 121.4, 117.0, 114.4, 109.4, 11.9, 76.2, 37.3, 34.8, 10.3 ppm.
IR (KBr): n˜=3182, 3079, 1731, 1635 cm¢1; ESIMS: m/z 499.11
[M+Na]+ ; HRMS-FAB m/z [M+H]+ calcd for: 477.1166, found:
477.1158; Anal. calcd for: C21H21FN4O6S: C 52.94, H 4.44, N 11.76, O
20.15, found: C 53.00, H 4.43, N 11.83, O 20.13.
General procedure for the preparation of hydroxyalkyl amides
4a,b : Ethanolamine (0.067 g, 1.1 mmol), HOBt (0.168 g, 1.1 mmol),
and EDCI (0.159 g, 1.3 mmol) were added in sequence to a solution
of the suitable 1,5-diarylpyrrole-3-acetic acid (5a,b) (0.300 g,
0.8 mmol) in a mixture of CH2Cl2/DMF (10:1 (v/v), 10 mL), under
a nitrogen atmosphere. An excess of TEA (0.17 mL, 1.3 mmol) was
then added dropwise and the reaction was stirred at RT. After 12 h,
the mixture was quenched with water (10 mL) and extracted with
CH2Cl2 (50 mLÕ3). The organic layer was washed with 1n HCl
(50 mL), NaHCO3 saturated solution (50 mL), brine (50 mL) and
dried over Na2SO4. After filtration and concentration of the organic
phase the so obtained crude material was purified by chromatog-
raphy on silica gel using ethyl acetate as eluent to give the desired
products as white powders.
2-(1-(4-Fluorophenyl)-2-methyl-5-(3-sulfamoylphenyl)-1H-pyrrol-
3-yl)-N-(2-hydroxyethyl)acetamide (4a): White powder, (0.271 g,
71% yield); mp: 155 8C; 1H NMR (400 MHz, [D6]DMSO): d=2.06 (s,
3H, CH3 pyrrolic), 3.12 (t, J=5.14 Hz, 2H, CO-NH-CH2-CH2-OH), 3.25
(s, 2H, C-CH2-CO), 3.41 (t, J=5.14 Hz, 2H, CO-NH-CH2-CH2-OH), 4.68
(br s, 1H, OH), 6.46 (s, 1H, CH pyrrolic), 7.11 (d, J=7.89 Hz, 2H, H
arom.), 7.23–7.31 (m, 6H, H arom. and SO2NH2), 7.57 (d, J=7.89 Hz,
2H, H arom.), 7.83 ppm (br s, 1H, CONH) ; 13C NMR (100 MHz,
[D6]DMSO): d :171.9, 160.2, 147.0, 144.0, 142.9, 134.6, 128.0, 127.3,
126.2, 121.9, 121.5, 116.0, 113.7, 66.9, 41.8, 33.9, 10.1 ppm; IR (KBr):
n˜=3358, 3342, 1752 cm¢1; ESIMS: m/z 454.12 [M+Na]+ ; HRMS-FAB
m/z [M+H]+ calcd for C21H22FN3O4S: 431.1315, found: 431.1318;
Anal. calcd for C21H22FN3O4S: C 58.46, H 5.14, N 9.74, O 14.83
found: C 58.40, H 5.20, N 9.67, O 14.80.
2-(1-(3-Fluorophenyl)-2-methyl-5-(3-sulfamoylphenyl)-1H-pyrrol-
3-yl)-N-(2-hydroxyethyl)acetamide (4b): White powder, (0.256 g,
67% yield); mp: 175 8C; 1H NMR (400 MHz, [D6]DMSO): d=2.04 (s,
3H, CH3 pyrrolic), 3.15 (t, J=5.62 Hz, 2H, CO-NH-CH2-CH2-OH), 3.27
(s, 2H, C-CH2-CO), 3.46 (t, J=5.62 Hz, 2H, CO-NH-CH2-CH2-OH), 4.69
(br s, 1H, OH), 6.48 (s, 1H, CH pyrrolic), 7.04 (d, J=7.82 Hz, 1H, H
arom.) 7.13 (d, J=8.07 Hz, 2H, H arom.), 7.19–7.33 (m, 4H, H arom.
and SO2NH2), 7.49–7.51 (m, 1H, H arom.), 7.60 (d, J=8.07 Hz, 2H, H
arom.), 7.90 ppm (br s, 1H, CONH) ; 13C NMR (100 MHz, [D6]DMSO):
d=171.3, 162.9, 142.5, 142.0, 141.6, 133.6, 129.2, 127.8, 126.5,
125.0, 120.9, 116.8, 112.6, 111.9, 106.8, 60.9, 40.8, 33.2, 9.6 ppm; IR
(KBr): n˜=3346, 3300, 1750 cm¢1; ESIMS: m/z 454.12 [M+Na]+ ;
HRMS-FAB m/z [M+H]+ calcd for C21H22FN3O4S: 431.1315, found:
431.1309; Anal. calcd for C21H22FN3O4S: C 58.46, H 5.14, N 9.74, O
14.83 found: C 58.90, H 5.17, N 9.77, O 14.86.
Biological assays
In vitro anti-inflammatory studies : The inhibitory activity of com-
pounds 1–4 against both COX-1 and COX-2 was determined by
the commercially available COX Inhibitor Screening Assay (Cayman
Chemical, Ann Arbor, MI, USA, cat. no. 560131), which exploits an
enzyme immunoassay to measure PGE2a produced by stannous
chloride reduction of PGEH2, derived in turn by reaction between
the target enzyme and the substrate, arachidonic acid. According
to the manufacturer’s protocol, test compounds (10 mL) were incu-
bated for 10 min at 37 8C with assay buffer (0.1m Tris-HCl, pH 8,
160 mL), Heme (10 mL), and either ovine COX-1 or human recombi-
nant COX-2 enzyme solution (10 mm). Arachidonic acid (10 mL) was
then added, and the resulting mixture was incubated for 2 min at
37 8C. Enzyme catalysis was stopped by adding HCl (1m, 10 mL)
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and the obtained PGEH2 was converted into PGE2a with saturated
stannous chloride solution (20 mL). Prostanoids were finally quanti-
fied by enzyme immunoassay (EIA), and their amount was deter-
mined through interpolation from a standard curve. The percent
inhibition of target enzyme by test compounds was calculated by
comparing PGE2a produced in compound-treated samples with
that of the compound-free, control sample. The highly selective
COX-2 inhibitor Dup-697 was used as the reference compound. All
the test compounds were dissolved into dilute assay buffer, and
their solubility was facilitated by using DMSO, whose concentration
never exceeded 1% in the final reaction mixture. The inhibitory
effect of test compounds was routinely estimated at a concentra-
tion of 10 mm. Results obtained are the mean of at least three de-
termination, carried out in triplicate (Table 1).
Ex vivo vasorelaxing activity : All the experimental procedures were
carried out following the guidelines of the European Community
Council Directive 86–609. The effects of the compounds were
tested on isolated thoracic aortic rings of male normotensive
Wistar rats (250–350 g). After a light ether anesthesia, rats were
sacrificed by cervical dislocation and bleeding. The aortae were im-
mediately excised, freed of extraneous tissues and the endothelial
layer was removed by gently rubbing the intimal surface of the
vessels with a hypodermic needle. Aortic rings (5 mm wide) were
suspended, under a preload of 2 g, in 20 mL organ baths, contain-
ing Tyrode solution (composition of saline in mm : NaCl 136.8, KCl
2.95, CaCl2 1.80, MgSO4 1.05, NaH2PO4 0.41, NaHCO3 11.9, glucose
5.5), thermostated at 37 8C and continuously gassed with a mixture
of O2 (95%) and CO2 (5%). Changes in tension were recorded by
means of an isometric transducer (Grass FTO3), connected with
a computerized system (Biopac). After an equilibration period of
60 min, the endothelium removal was confirmed by the adminis-
tration of acetylcholine (ACh; 10 mm) to KCl (30 mm) pre-contracted
vascular rings. A relaxation <10% of the KCl-induced contraction
was considered representative of an acceptable lack of the endo-
thelial layer, while the organs, showing a relaxation P10% (i.e. sig-
nificant presence of the endothelium), were discarded. From 30 to
40 min after the confirmation of the endothelium removal, the
aortic preparations were contracted by a single concentration of
KCl (30 mm) and when the contraction reached a stable plateau,
threefold increasing concentrations of the tested compounds
(1 nm–10 mm) were added. Preliminary experiments showed that
the KCl (30 mm)-induced contractions remained in a stable tonic
state for at least 40 min. The same experiments were carried out
also in the presence of a well-known GC inhibitor: ODQ 1 mm
which was incubated in aortic preparations after the endothelium
removal confirmation. The vasorelaxing efficacy was evaluated as
maximal vasorelaxing response (Emax), expressed as a percentage of
the contractile tone induced by KCl 30 mm. When the limit concen-
tration 10 mm (the highest concentration that could be adminis-
tered) of the tested compounds did not reach the maximal effect,
the parameter of efficacy represented the vasorelaxing response,
expressed as a percentage of the contractile tone induced by KCl
30 mm, evoked by this limit concentration. The parameter of po-
tency (pIC50) was calculated as negative logarithm of the molar
concentration of the tested compounds evoking a half reduction
of the contractile tone induced by KCl 30 mm. The pIC50 could not
be calculated for those compounds showing an efficacy parameter
lower than 50%. The parameters of efficacy and potency were ex-
pressed as mean  standard error, for 6 experiments. Two-way
ANOVA was selected as statistical analysis, P<0.05 was considered
representative of significant statistical differences. Experimental
data were analyzed by a computer fitting procedure (software:
GraphPad Prism 4.0).
In vivo studies : All animal manipulations were carried out according
to the European Community guidelines for animal care (DL 116/92,
application of the European Communities Council Directive of 24
November 1986 (86/609/EEC). The ethical policy of the University
of Florence complies with the Guide for the Care and Use of Labo-
ratory Animals of the US National Institutes of Health (NIH Publica-
tion No. 85–23, revised 1996; University of Florence assurance
number: A5278–01). Formal approval to conduct the experiments
described was obtained from the Animal Subjects Review Board of
the University of Florence. Experiments involving animals have
been reported according to ARRIVE guidelines.[39] All efforts were
made to minimize animal suffering and to reduce the number of
animals used. Male Swiss albino mice (23–25 g) and Sprague–
Dawley or Wistar rats (150–200 g) were used. The animals were fed
with a standard laboratory diet and tap water ad libitum and kept
at 23 8C with a 12 h light/dark cycle, with light on at 7:00 AM. The
analgesic activity of compounds was assessed by performing the
abdominal constriction test, using mice into which a solution of
acetic acid (0.6%, 10 mLkg¢1) had been injected intraperitoneally
(i.p.). The number of stretching movements was counted for
10 min, starting 5 min after administration.
New COX inhibitor preparation and docking : All calculations were
performed using a blade (Intel-Xeon CPU) running Debian GNU/
Linux “Jessie” 8.1 64-bit operating system. Ligand’s 3D conforma-
tions were generated from scratch. Marvin was used for drawing,
displaying and characterizing chemical structures, Marvin 15.1.12.0,
2015, ChemAxon (www.chemaxon.com). OpenBabel was used to
generate random conformation to run the cross-docking experi-
ments by Vina COX-2. Docking procedure and detail were the
same as previously reported.[31]
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